About ARMO BioSciences:
Founded in 2012, ARMO BioSciences is a clinical-stage company developing immunotherapies focused on multiple difficult-to-treat oncology indications. The company's lead immunotherapy AM0010, a PEGylated form of recombinant human IL-10, primes the tumor micro-environment for immune-mediated therapies and has demonstrated durable clinical responses in several types of cancer, as both a single agent and in combination with standard-of-care chemotherapy or anti-Programmed Cell Death Protein (anti-PD-1) monoclonal antibodies. ARMO plans to initiate the first of several registration-enabling phase 2/3 studies for AM0010 in solid tumors. The company also has a robust pipeline of therapeutic cytokines and an anti-PD-1 checkpoint inhibitor.
For more information, please visit www.armobio.com.
Scott Ogg, Ph.D.
Vice President Corporate Development and Operations
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/armo-biosciences-to-present-at-the-jefferies-immuno-oncology-summit-300241706.html
SOURCE ARMO BioSciences, Inc.